Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine | NEJM

A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. (Funded by Novavax; EudraCT number, 2020-004123-16. opens in new tab.) Source: Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine | NEJM